Researchers in the Airan Lab have developed a noninvasive method using low intensity transcranial ultrasound to drive cerebrospinal fluid (CSF) glymphatic and lymphatic flow to clear brain injury waste products from CSF and brain interstitium.
Researchers at Stanford University and Washington University in St. Louis have discovered a novel molecular pathway for the treatment of opioid overdose.
Current challenges in corneal endothelial cells (CEC) transplantation include the limited availability of donor grafts and the inability of CECs to regenerate within the body.
Stanford researchers have discovered that tumors increase the risk of atherosclerosis by regulating expression of a specific gene that stimulates angiogenesis and intraplaque neovessel formation.
Stanford researchers have developed a targeted therapy for Alzheimer's disease that focuses on inhibiting the spread of tau protein, a key factor in disease progression.
Elastin-like polypeptides (ELPs) are promising biomaterials for medical applications due to their non-immunogenicity, scalable synthesis, and tunable self-assembly.
Stanford researchers have created a new strategy for collecting and integrating human microbiome, multi-omics, and immune cell activation data that reveals new insights into the roles of different bacterial strains in human health.
Researchers in Prof. Paul George's laboratory have patented a conductive polymer scaffold designed to electrically stimulate neural progenitor cells (NPCs) for enhanced neural regeneration.
Stanford scientists have developed cross-reactive antibodies that can bind human and murine NKp46 on NK cells and induce cytotoxicity and proliferation.
Researchers at Stanford have developed a novel deep-learning-based tool called CytoTRACE2 that interprets single-cell RNA sequencing (scRNA-seq) to enable the discovery of regenerative cells across all tissue types and novel targets in cancer and other diseases.
Stanford researchers in Dr. Mahajan's laboratory have discovered biomarkers to differentiate between infectious (endophthalmitis) and non-infectious uveitis; and, to accurately categorize the types of infectious uveitis.
Stanford researchers have discovered the first of its kind gene therapy vector to treat eye diseases of the non-pigmented ciliary epithelium cells (NPCECs).
Scientists in Sergiu Pasca's group at Stanford University have used patient-derived organoids, assembloids and in vivo transplantation to discover and validate an antisense oligonucleotide drug for the treatment of Timothy syndrome.